The 5 indifferent analyst ratings for Akebia Therapeutics indicate that there is no strong consensus on the stock's direction. However, the average price target of $1.7 suggests a potential upside from the current price of $1.21. The 36.0% increase in the average price target from the previous average indicates that analysts may be becoming more optimistic about the stock. Given this information, the short-term impact on AKBA's stock price is neutral.